Product
HRS-8080; Dalpiciclib Isethionate
1 clinical trial
1 indication
Indication
Breast CancerClinical trial
A Multicenter, Open Phase Ib/II Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-8080 in Combination With Dalpiciclib Isethionate Tablets in Patients With ER-positive, HER2-negative Unresectable or Metastatic Breast CancerStatus: Recruiting, Estimated PCD: 2025-10-31